Cancer Immunotherapy Program

Program Directors

  • Crystal Mackall

    Crystal Mackall

    Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine

  • Edgar Engleman

    Edgar Engleman

    Professor of Pathology and of Medicine (Immunology and Rheumatology)

About Cancer Immunotherapy

The Cancer Immunotherapy Program brings together basic scientists, translational investigators and clinician scientists to discover fundamental principles that regulate immune responses to cancer and to translate this understanding into novel cancer therapies. A major focus is on comprehensive immune profiling, using tools for high dimensional analysis of immune responses. Fundamental modeling of cancer therapeutics is conducted in murine models and the Program has an increasing effort in translating novel therapeutics to the clinic and utilizing patient samples to study the tumor:immune interface.

Program Aims: 

  • Discover principles regarding the biological basis of immune responses in the context of cancer
  • Develop and use high dimensional and cutting edge technologies and animal modeling to probe immune function and cancer/immune interactions
  • Translate novel therapies to generate robust and effective antitumor immune responses in patients